PubRank

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®)

Clinical Trial ID NCT01179048

PubWeight™ 41.54‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01179048

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. START INVESTS P 13. N Engl J Med 2016 7.04
2 Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2013 2.66
3 Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig 2013 1.55
4 The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012 1.32
5 Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2012 1.20
6 Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2016 1.15
7 Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2014 1.05
8 Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol 2014 1.00
9 SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 2016 0.98
10 Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 2015 0.93
11 Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013 0.92
12 Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. J Card Fail 2014 0.90
13 Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol 2014 0.88
14 Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. J Diabetes Investig 2015 0.87
15 Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications 2014 0.86
16 Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125. Diabetes Care 2013 0.86
17 LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. Pancreas 2014 0.85
18 How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment. Diabetes Care 2013 0.84
19 The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol 2013 0.83
20 Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents. Nephrol Dial Transplant 2015 0.82
21 Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. J Cereb Blood Flow Metab 2015 0.81
22 Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol 2014 0.80
23 Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial. Diabetes Ther 2016 0.79
24 Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol 2016 0.79
25 Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? Diabetes Ther 2016 0.77
26 LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc Diabetol 2016 0.76
27 LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. Diabetes Obes Metab 2015 0.76
28 Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Ther Adv Drug Saf 2012 0.76
29 LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. J Hypertens 2016 0.76
30 The evolving role of bariatric surgery in patients with type 1 diabetes and obesity. Integr Obes Diabetes 2016 0.75
31 Comment on Andersen et al, pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas 2014 0.75
32 Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements. Diabetes Metab Syndr Obes 2015 0.75
33 Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. Clin Pharmacol Ther 2015 0.75
34 Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia. Med Arch 2014 0.75
35 Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial. Herz 2016 0.75
36 Blood pressure and cardiovascular effects of new and emerging antidiabetic agents. Curr Hypertens Rep 2014 0.75
37 Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists. Diabetes Metab Res Rev 2016 0.75
38 Cardiovascular effects of anti-diabetes drugs. Expert Opin Drug Saf 2016 0.75
39 LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. Diabetol Metab Syndr 2016 0.75
40 Diabetes Drugs and Cardiovascular Safety. Endocrinol Metab (Seoul) 2016 0.75
41 Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab 2015 0.75
42 Linagliptin as add-on therapy to insulin for patients with type 2 diabetes. Vasc Health Risk Manag 2013 0.75
Next 100